NYSEMKT: CCELCryo Cell International Inc Stock
$5.82-0.21 (-3.48%)
Updated Apr 17, 2025
CCEL Price
$5.82
Fair Value Price
N/A
Market Cap
$47.04M
52 Week Low
$4.96
52 Week High
$9.50
P/E
582x
P/B
-3.21x
P/S
1.99x
PEG
N/A
Dividend Yield
4.3%
Revenue
$32.10M
Earnings
$128.71k
Gross Margin
75.8%
Operating Margin
14.47%
Profit Margin
0.4%
Debt to Equity
-5.39
Operating Cash Flow
$7M
Beta
0.1
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
CCEL Overview
Cryo-Cell International, Inc. engages in the cellular processing and cryogenic cellular storage with a focus on the collection and preservation of umbilical cord blood stem cells for family use. It provides cord tissue service that stores a section of the umbilical cord tissue, a source of mesenchymal stem cells that are used in regenerative medicine to treat a range of conditions, including heart, kidney, ALS, wound healing, and auto-immune diseases. The company also manufactures and sells PrepaCyte CB processing system, a technology used to process umbilical cord blood stem cells. It stores approximately 500,000 cord blood and cord tissue stem cells worldwide. The company markets its cord blood stem cell preservation services directly to expectant parents, as well as by distributing information through obstetricians, pediatricians, childbirth educators, certified nurse-midwives, and other related healthcare professionals. Cryo-Cell International, Inc. was founded in 1989 and is headquartered in Oldsmar, Florida.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine CCEL's potential to beat the market
- CCEL doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Medical Care Facility
Industry Rating
B
CCEL
RankedUnranked of 42
RankedUnranked of 42
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $12.82 | A | |
| $12.51 | A | |
| $174.80 | A |
Be the first to know about important CCEL news, forecast changes, insider trades & much more!
CCEL News
Overview
Due Diligence Score
–
Industry Average (30)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how CCEL scored across 38 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
CCEL was unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
CCEL is poor value based on its earnings relative to its share price (582x), compared to the US market average (27.98x)
P/E vs Market Valuation
CCEL is poor value based... subscribe to Premium to read more.
P/E vs Industry Valuation
There are 35 more CCEL due diligence checks available for Premium users.
Valuation
CCEL price to earnings (PE)
For valuing profitable companies with steady earnings
Company
582x
Industry
14.77x
Market
27.98x
CCEL is poor value based... subscribe to Premium to read more.
P/E vs Industry Valuation
CCEL is poor value based... subscribe to Premium to read more.
P/E vs Market Valuation
CCEL price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-3.21x
Industry
4.22x
CCEL's financial health
Profit margin
Revenue
$8.0M
Net Income
$282.9k
Profit Margin
3.5%
CCEL's Earnings (EBIT) of $4.65M... subscribe to Premium to read more.
Interest Coverage Financials
CCEL's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$64.4M
Liabilities
$79.0M
Debt to equity
-5.39
CCEL's short-term liabilities ($21.72M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CCEL's long-term liabilities ($57.32M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CCEL's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
CCEL's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$954.1k
Investing
-$287.5k
Financing
-$1.0M
CCEL's operating cash flow ($7.32M)... subscribe to Premium to read more.
Debt Coverage Financials
CCEL vs Medical Care Facility Stocks
Cryo Cell International Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.